株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

血液癌治療:世界市場 2023年

Blood Cancer Therapeutics: Global Markets to 2023

発行 BCC Research 商品コード 763978
出版日 ページ情報 英文 174 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.43円で換算しております。
Back to Top
血液癌治療:世界市場 2023年 Blood Cancer Therapeutics: Global Markets to 2023
出版日: 2018年12月28日 ページ情報: 英文 174 Pages
概要

世界の血液癌治療市場は、2018年の385億米ドルから2023年までに648億米ドルへ拡大すると予測され、この間は11.0%のCAGR (年間複合成長率) が見込まれています。

当レポートでは、世界の血液癌治療市場について調査し、市場の概要、市場動向、および市場成長促進因子などの分析を提供しており、主要地域・疾病タイプ別の分析、および主要企業のプロファイルなどをまとめています。

第1章 イントロダクション

第2章 サマリー・ハイライト

第3章 市場概要

  • 市場定義・概要
  • 血液癌のタイムライン (研究におけるマイルストーン)
  • 製品認可
  • スクリーニング・予防プログラム
  • 血液癌の啓発月間
  • The Heroes Among Us
  • Spot Leukemia
  • Make Blood Cancer Visible

第4章 市場ダイナミクス・技術背景

  • 市場成長の促進要因
  • 課題

第5章 市場分析:疾病タイプ別

  • 白血病
  • 急性リンパ芽球性白血病 (ALL)
  • 急性骨髄性白血病 (AML)
  • 慢性骨髄性白血病 (CML)
  • 小児白血病
  • 非ホジキンリンパ腫
  • ホジキンリンパ腫
  • 多発性骨髄腫
  • 有毛細胞白血病 (HCL)

第6章 血液癌治療の投薬計画

  • 標的療法
  • 免疫療法
  • 化学療法
  • 薬物併用療法
  • CAR-T 療法

第7章 市場分析:地域別

  • 北米の血液癌治療市場
  • 欧州の血液癌治療市場
  • アジア太平洋の血液癌治療市場
  • その他の血液癌治療市場

第8章 パイプライン分析

  • 研究開発の概要
  • 開発中の血液癌治療薬
  • 有望なパイプライン分子

第9章 規制・医療費償還構造

  • 規制の概要
  • 価格・医療費償還の概要

第10章 競合情勢・主な発展

  • 市場構造の分析
  • ベストセラー薬の特許期限切れ
  • 主な産業の発展

第11章 企業プロファイル

  • ABBVIE INC.
  • AMGEN INC.
  • ASTRAZENECA PLC
  • BOEHRINGER INGELHEIM PHARMACEUTICALS INC.
  • BRISTOL-MYERS SQUIBB CO.
  • CELGENE CORP.
  • GILEAD SCIENCES INC.
  • GLAXOSMITHKLINE PLC
  • F. HOFFMANN-LA ROCHE LTD.
  • JANSSEN GLOBAL SERVICES LLC
  • MERCK & CO., INC.
  • NOVARTIS AG
  • PFIZER INC.
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.

第12章 付録:用語

図表

List of Tables

  • Summary Table: Global Market for Blood Cancer Therapeutics, by Disease Type, Through 2023
    • Table 1: Type of Blood Cancers (Hematological Cancer)
    • Table 2: Milestones in the History of Leukemia
    • Table 3: Product Approvals, 2016-2018
    • Table 4: Classification of Leukemia
    • Table 5: Types of Leukemia, Key Features, Occurrence
    • Table 6: Diagnostic Examination for Leukemia
    • Table 7: PCR Tests
    • Table 8: Additional Tests
    • Table 9: Treatments for Leukemia
    • Table 10: Newer Classes of Drugs
    • Table 11: Types of Stem Cell Transplantation
    • Table 12: Types of Targeted Therapies
    • Table 13: Types of Radiation Therapies
    • Table 14: Global Market for Leukemia Therapeutics, by Subtype, Through 2023
    • Table 15: Global Market for Leukemia Therapeutics, by Region, Through 2023
    • Table 16: Acute Lymphoblastic Leukemia (ALL) Treatment
    • Table 17: Therapies Approved for Acute Lymphoblastic Leukemia (ALL)
    • Table 18: Global Market for Acute Lymphocytic Leukemia (ALL) Therapeutics, by Region, Through 2023
    • Table 19: Therapies Approved for Acute Myeloid Leukemia
    • Table 20: Global Market for Acute Myeloid Leukemia Therapeutics, by Region, Through 2023
    • Table 21: Therapies Approved for Chronic Myeloid Leukemia
    • Table 22: Global Market for Chronic Myeloid Leukemia Therapeutics, by Region, Through 2023
    • Table 23: Therapies Approved for Chronic Lymphocytic Leukemia
    • Table 24: Global Market for Chronic Lymphocytic Leukemia Therapeutics, by Region, Through 2023
    • Table 25: Childhood Leukemia, Five-Year Relative Survival, Age 0-14, 1975-2014
    • Table 26: Childhood Leukemia, Five-Year Relative Survival, Age 0-19, 1975-2014
    • Table 27: Subtypes of Non-Hodgkin Lymphoma, by Type
    • Table 28: Non-Hodgkin Lymphoma, Stages and Modifying Features
    • Table 29: Drugs Approved for Non-Hodgkin Lymphoma
    • Table 30: Monoclonal Antibodies Approved for Non-Hodgkin Lymphoma
    • Table 31: Subtypes of Hodgkin Lymphoma, by Type
    • Table 32: Hodgkin Lymphoma, Stages and Modifying Features
    • Table 33: Therapies Approved for Classical Hodgkin Lymphoma
    • Table 34: Hodgkin Lymphoma, Annual Incidence Rates, 2011-2015
    • Table 35: Global Market for Lymphoma Therapeutics, by Region, Through 2023
    • Table 36: Effect of Treatment on Multiple Myeloma
    • Table 37: Therapies Approved for Multiple Myeloma
    • Table 38: Chemotherapy Drugs for Multiple Myeloma
    • Table 39: Effect of Treatment on Multiple Myeloma
    • Table 40: Global Market for Multiple Myeloma Therapeutics, by Region, Through 2023
    • Table 41: Drug Approved for Hairy Cell Leukemia
    • Table 42: Global Market for Blood Cancer Therapeutics, by Region, Through 2023
    • Table 43: North American Estimated Incidence of Blood Cancer, by Country, 2018
    • Table 44: North American Market for Blood Cancer Therapeutics, by Disease Type, Through 2023
    • Table 45: North American Market for Leukemia Therapeutics, by Subtype, 2017-2023
    • Table 46: North American Market for Blood Cancer Therapeutics, by Country, Through 2023
    • Table 47: European Estimated Incidence of Blood Cancer, by Country, 2018
    • Table 48: European Market for Blood Cancer Therapeutics, by Disease Type, Through 2023
    • Table 49: European Market for Leukemia Therapeutics, by Subtype, 2017-2023
    • Table 50: European Market for Blood Cancer Therapeutics, by Country, Through 2023
    • Table 51: Asia-Pacific Estimated Incidence of Blood Cancer, by Country, 2018
    • Table 52: Asia-Pacific Market for Blood Cancer Therapeutics, by Disease Type, Through 2023
    • Table 53: Asia-Pacific Market for Leukemia Therapeutics, by Subtype, Through 2023
    • Table 54: Asia-Pacific Market for Blood Cancer Therapeutics, by Country, Through 2023
    • Table 55: Rest of the World Estimated Incidence of Blood Cancer, by Country, 2018
    • Table 56: Rest of the World Market for Blood Cancer Therapeutics, by Disease Type, Through 2023
    • Table 57: Rest of the World Market for Leukemia Therapeutics, by Subtype, Through 2023
    • Table 58: Pipeline: Phase I, 2018
    • Table 59: Pipeline, Phase II, 2018
    • Table 60: Pipeline, Phase III, 2018
    • Table 61: Potential Drugs, Indication and Estimated Filing, 2018
    • Table 62: Patent Expiration of Blood Cancer Drugs
    • Table 63: Key Developments, 2016-2018
    • Table 64: AbbVie Inc.: Marketed Products
    • Table 65: AbbVie Inc.: Net Revenue, 2015-2017
    • Table 66: Amgen Inc.: Marketed Products
    • Table 67: AstraZeneca plc: Marketed Products
    • Table 68: AstraZeneca plc: Net Revenue, 2014-2017
    • Table 69: Boehringer Ingelheim GmbH: Net Revenue, 2015-2017
    • Table 70: Bristol-Myers Squibb Co.: Marketed Products
    • Table 71: Bristol-Myers Squibb Co.: Net Revenue, 2014-2016
    • Table 72: Celgene Corp.: Marketed Products
    • Table 73: Celgene Corp.: Net Revenue, 2015-2016
    • Table 74: Gilead Sciences Inc.: Net Revenue, 2014-2016
    • Table 75: GlaxoSmithKline plc: Net Revenue, 2014-2016
    • Table 76: F. Hoffmann-La Roche Ltd.: Marketed Products
    • Table 77: F. Hoffmann-La Roche Ltd.: Net Revenue, 2015-2017
    • Table 78: Johnson & Johnson Inc.: Net Revenue, 2014-2016
    • Table 79: Merck & Co., Inc.: Marketed Products
    • Table 80: Merck & Co., Inc.: Net Revenue, 2014-2016
    • Table 81: Novartis AG: Marketed Products
    • Table 82: Novartis AG: Net Revenue, 2014-2016
    • Table 83: Pfizer Inc.: Marketed Products by Indication
    • Table 84: Pfizer Inc.: Net Revenue, 2015-2017
    • Table 85: Teva Pharmaceutical Industries Ltd.: Marketed Products
    • Table 86: Teva Pharmaceutical Industries Ltd.: Net Revenue, 2015-2017
    • Table 87: Acronyms Used in This Blood Cancer Therapeutics Report
    • Table 88: Glossary of Terms Used in This Blood Cancer Therapeutics Report

List of Figures

  • Summary Figure: Global Market for Blood Cancer Therapeutics, by Disease Type, 2017-2023
    • Figure 1: Percentage Share of Global Blood Cancer Prevalence, 2018
    • Figure 2: Percentage Share of Cancer Incidence in the U.S., by Top 10 Cancer Types, 2018
    • Figure 3: U.S. Leukemia Statistics, by Annual Rates (per 100,000 Population) and Number of New Cases (Total Cases), 1999-2016
    • Figure 4: Awareness Campaigns
    • Figure 5: Types of Leukemia, Key Features, Occurrence
    • Figure 6: Global Market for Leukemia Therapeutics, 2017-2023
    • Figure 7: Global Market for Leukemia Therapeutics, by Subtype, 2017-2023
    • Figure 8: Global Market Share for Leukemia Therapeutics, by Subtype, 2018
    • Figure 9: Global Market Share for Leukemia Therapeutics, by Subtype, 2023
    • Figure 10: Global Market for Leukemia Therapeutics, by Region, 2017-2023
    • Figure 11: Global Market for Acute Lymphocytic Leukemia (ALL) Therapeutics, 2017-2023
    • Figure 12: Global Market for Acute Lymphocytic Leukemia (ALL) Therapeutics, by Region, 2017-2023
    • Figure 13: Global Market for Acute Myeloid Leukemia Therapeutics, 2017-2023
    • Figure 14: Global Market for Acute Myeloid Leukemia Therapeutics, by Region, 2017-2023
    • Figure 15: Global Market for Chronic Myeloid Leukemia Therapeutics, 2017-2023
    • Figure 16: Global Market for Chronic Myeloid Leukemia Therapeutics, by Region, 2017-2023
    • Figure 17: Global Market for Chronic Lymphocytic Leukemia Therapeutics, 2017-2023
    • Figure 18: Global Market for Chronic Lymphocytic Leukemia Therapeutics, by Region, 2017-2023
    • Figure 19: Global Market for Lymphoma Therapeutics, 2017-2023
    • Figure 20: Global Market for Lymphoma Therapeutics, by Region, 2017-2023
    • Figure 21: Global Market for Multiple Myeloma Therapeutics, 2017-2023
    • Figure 22: Global Market for Multiple Myeloma Therapeutics, by Region, 2017-2023
    • Figure 23: Global Market for Blood Cancer Therapeutics, 2017-2023
    • Figure 24: Global Market for Blood Cancer Therapeutics, by Region, 2017-2023
    • Figure 25: Percentage Share of North American Leukemia (Estimated) Incidence, by Country, 2018
    • Figure 26: Estimated Leukemia Incidence in the United States, by Type, 2016-2018
    • Figure 27: Percentage Share of Estimated Blood Cancer Incidence in Canada, 2016
    • Figure 28: Percentage Share of North American Non-Hodgkin Lymphoma Estimated Incidence, by Country, 2018
    • Figure 29: Percentage Share of North American Hodgkin Lymphoma Estimated Incidence, by Country, 2018
    • Figure 30: North American Market for Blood Cancer Therapeutics, 2017-2023
    • Figure 31: North American Market for Blood Cancer Therapeutics, by Disease Type, 2017-2023
    • Figure 32: North American Market for Leukemia Therapeutics, by Subtype, 2017-2023
    • Figure 33: North American Market for Blood Cancer Therapeutics, by Country, 2017-2023
    • Figure 34: U.K. Top 20 Common Causes of Cancer Death, by Country, 2016
    • Figure 35: European Market for Blood Cancer Therapeutics, 2017-2023
    • Figure 36: European Market for Blood Cancer Therapeutics, by Disease Type, 2017-2023
    • Figure 37: European Market for Leukemia Therapeutics, by Subtype, 2017-2023
    • Figure 38: European Market for Blood Cancer Therapeutics, by Country, 2017-2023
    • Figure 39: Asia-Pacific Market for Blood Cancer Therapeutics, 2017-2023
    • Figure 40: Asia-Pacific Market for Blood Cancer Therapeutics, by Disease Type, 2017-2023
    • Figure 41: Asia-Pacific Market for Leukemia Therapeutics, by Subtype, 2017-2023
    • Figure 42: Asia-Pacific Market for Blood Cancer Therapeutics, by Country, 2017-2023
    • Figure 43: Rest of the World Market for Blood Cancer Therapeutics, 2017-2023
    • Figure 44: Rest of the World Market for Blood Cancer Therapeutics, by Disease Type, 2017-2023
    • Figure 45: Rest of the World Market for Leukemia Therapeutics, by Subtype, 2017-2023
    • Figure 46: Federal and Inter-provincial Approval System for Cancer Drugs in Canada
    • Figure 47: AbbVie Inc.: Revenue Share, by Country, 2017
    • Figure 48: Boehringer Ingelheim GmbH: Revenue Share, by Region, 2017
    • Figure 49: Boehringer Ingelheim GmbH: Revenue Share, by Business Segment, 2017
    • Figure 50: Boehringer Ingelheim GmbH: R&D Expenditures, 2015-2017
    • Figure 51: Bristol-Myers Squibb Co.: Revenue Share, by Country/Region, 2017
    • Figure 52: Gilead Sciences Inc.: Revenue Share, by Business Segment, 2016
    • Figure 53: Gilead Sciences Inc.: Revenue Share, by Country/Region, 2016
    • Figure 54: GlaxoSmithKline plc: Revenue Share, by Business Segment, 2016
    • Figure 55: GlaxoSmithKline plc: Revenue Share, by Region, 2016
    • Figure 56: F. Hoffmann-La Roche Ltd.: Revenue Share, by Segment, 2017
    • Figure 57: F. Hoffmann-La Roche Ltd.: Revenue Share, by Region, 2017
    • Figure 58: Johnson & Johnson Inc.: Revenue Share, by Business Segment, 2016
    • Figure 59: Johnson & Johnson Inc.: Revenue Share, by Country/Region, 2016
    • Figure 60: Merck & Co., Inc.: Revenue Share, by Business Segment, 2016
    • Figure 61: Merck & Co., Inc.: Revenue Share, by Country/Region, 2016
    • Figure 62: Novartis AG: Revenue Share, by Country/Region, 2016
    • Figure 63: Novartis AG: Revenue Share, by Business Segment, 2016
    • Figure 64: Pfizer Inc.: Revenue Share, by Country/Region, 2016
    • Figure 65: Pfizer Inc.: Revenue Share, by Business Segment, 2016
    • Figure 66: Teva Pharmaceutical Industries Ltd.: Revenue Share, by Region, 2017
    • Figure 67: Teva Pharmaceutical Industries Ltd.: Revenue Share, by Business Segment, 2016
目次
Product Code: PHM210A

Report Highlights:

The global market for blood cancer therapeutics should grow from $38.5 billion in 2018 to $64.8 billion by 2023 at a compound annual growth rate (CAGR) of 11.0% from 2018 to 2023.

The global leukemia therapeutic market should grow from $14.1 billion in 2018 to $23.2 billion by 2023 at a CAGR of 10.6% from 2018 to 2023.

The global lymphoma therapeutic market should grow from $10.5 billion in 2018 to $18.6 billion by 2023 at a CAGR of 12.2% from 2018 to 2023.

Report Scope:

This report organizes information from diverse sources into a comprehensive report that includes an overview, market dynamics, disease type, leading blockbuster drug profiles, regulations, reimbursement and patents. It analyzes prevailing blood cancer treatment guidelines in different geographic regions. The scope of the blood cancer therapeutic market is restricted to three disease areas: leukemia, lymphoma and multiple myeloma. Leukemia is classified into four sub-segments: chronic myeloid leukemia (CML), acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). This report includes an overview of the global market scenario for blood cancer treatments with base year data from 2017, estimations for 2018 and forecasts for 2019 to 2023, using CAGR projections. Market data in value terms is provided at global, regional and country levels for disease areas. This report forecasts the global market by disease area and discusses market data for leukemia, lymphoma and myeloma. This report involves regional market overviews for North America, Europe, Asia-Pacific and Rest of the World. Regional overviews provide information on the epidemiology of blood cancer by country and region and detailed market data for each region.

Market dynamics, such as trends and challenges, are discussed in the report. Global market drivers, trends and challenges influencing the blood cancer therapeutic market are also captured in this report. Detailed analyses of competitive environments, blockbuster drugs, pipelines, patents, the regulatory landscape and the reimbursement landscape are included in the report. The regulatory scenario is discussed for the United States, Europe and Japan to provide an overview of regulations for new drug launches. The reimbursement scenario is outlined for the United States and Europe to provide an overview to readers. The pipeline analysis chapter discusses four major disease areas to provide details about major pipeline developments. The competitive landscape discusses major manufacturers involved in the blood cancer therapeutic market, key developments and product offerings.

Report Includes:

  • 41 data tables and 48 additional tables
  • An overview of the global blood cancer therapeutics markets within the industry
  • Analyses of global market trends with data from 2017 and 2018, and projections of compound annual growth rates (CAGRs) through 2023
  • Regional dynamics of the market covering North America, Europe, Asia-Pacific and other emerging economies
  • Discussion of major drivers, trends and challenges influencing blood cancer therapeutics market
  • Information on the competitive environments, blockbuster drugs, pipeline analysis, patent analysis, and regulatory and reimbursement structure
  • Coverage of regulatory environments for the United States, Europe and Japan; and information pertaining to the regulations for new drug launches
  • A look at the reimbursement scenario outlined for the United States and Europe, and Pipeline analysis encompassing major disease area
  • Examination of the competitive landscape and description of the major manufacturers involved in the blood cancer therapeutics market, key developments and product offerings
  • Company profiles of leading market players, including AbbVie Inc., AstraZeneca plc, Bristol-Myers Squibb Co., GlaxoSmithKline plc, F. Hofmann-La Roche Ltd., and Novartis AG

Table of Contents

Chapter 1: Introduction

  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Information Sources
  • Methodology
  • Geographic Breakdown
  • Analyst's Credentials
  • BCC Custom Research
  • Related BCC Research Reports

Chapter 2: Summary and Highlights

Chapter 3: Market Overview

  • Market Definitions and Overview
    • Risk Factors
    • Symptoms
    • Diagnosis
    • Treatment and Therapy
  • Blood Cancer Timeline (Milestones in Research)
  • Product Approvals
  • Screening and Prevention Programs
  • Blood Cancer Awareness Month
  • The Heroes Among Us Campaign
  • Spot Leukemia Campaign
  • Make Blood Cancer Visible Campaign

Chapter 4: Market Dynamics and Technology Background

  • Market Drivers
    • Rising Incidence of Blood Cancer
    • Highly Sensitive Tests to Detect Minimal Residual Disease
    • Rising Government and Private Funding for Cancer Treatment
  • Challenges
    • Absence of Screening Programs for Early Detection
    • Low Awareness

Chapter 5: Market Breakdown by Disease Type

  • Leukemia
    • Lymphocytic Leukemias
    • Myelogenous Leukemias
    • Symptoms
    • Causes
    • Diagnosis
    • Treatment
    • Stages
    • Treatment and Therapies
    • Market Size and Analysis
  • Acute Lymphoblastic Leukemia (ALL)
    • Market Size and Analysis
  • Acute Myeloid Leukemia (AML)
    • Treatment and Therapies
    • Market Size and Analysis
  • Chronic Myeloid Leukemia (CML)
    • Market Size and Analysis
    • Chronic Lymphocytic Leukemia (CLL)
    • First-Line Treatment Regimen
    • Second-Line Treatment Regimen
    • Market Size and Analysis
  • Childhood Leukemia
  • Non-Hodgkin Lymphoma
    • Causes and Risk Factors
    • Signs and Symptoms
    • Diagnosis
    • Staging
    • Treatment
    • Non-Hodgkin Lymphoma Treatment for Children, Adolescents and Young Adults
  • Hodgkin Lymphoma
    • Causes and Risk Factors
    • Signs and Symptoms
    • Diagnosis
    • Staging
    • Treatment
    • Hodgkin Lymphoma Treatment for Children and Young Adults
    • Lymphoma Therapeutics: Market Size and Analysis
  • Multiple Myeloma
    • Symptoms
    • Causes and Risk Factors
    • Treatment and Therapies
    • Market Size and Analysis
  • Hairy Cell Leukemia (HCL)
    • Immunotherapy

Chapter 6: Blood Cancer Treatment Regimens

  • Targeted Therapy
    • B-Cell Leukemia/Lymphoma-2 (BCL-2) Inhibitors
    • FLT3 Inhibitors
    • Kinase Inhibitors
    • IDH Inhibitors
    • Proteasome Inhibitors
  • Immunotherapy
    • Monoclonal Antibodies (mAb) Therapy
  • Chemotherapy
    • DNA-Damaging Agents or Alkylating Agents
    • Antitumor Antibiotics
    • Antimetabolites
    • DNA-Repair Enzyme Inhibitors
    • Topoisomerase Inhibitors
  • Drug Combination Therapies
    • Leukemia
    • Non-Hodgkin Lymphoma
  • CAR-T Therapy

Chapter 7: Market Breakdown by Region

  • North American Blood Cancer Therapeutic Market
    • Epidemiology
    • Market Size and Analysis
  • European Blood Cancer Therapeutic Market
    • Epidemiology
    • Market Size and Analysis
  • Asia-Pacific Blood Cancer Therapeutic Market
    • Epidemiology
    • Market Size and Analysis
  • Rest of the World Blood Cancer Therapeutic Market
    • Epidemiology
    • Market Size and Analysis

Chapter 8: Pipeline Analysis

  • Research and Development Overview
  • Blood Cancer Drugs Under Development
  • Promising Pipeline Molecules
    • Venclexta (AbbVie Inc.)
    • Empliciti (Bristol-Myers Squibb Co.)
    • Aplidin (PharmaMar)
    • SRF231 (Surface Oncology)

Chapter 9: Regulatory and Reimbursement Structure

  • Overview of Regulations
    • United States
    • Canada
    • Europe
    • Japan
    • China
  • Overview of Pricing and Reimbursement
    • United States
    • Europe
    • Japan

Chapter 10: Competitive Landscape and Key Developments

  • Market Structure Analysis
  • Patent Expiration for Blockbuster Drugs
  • Key Industry Developments

Chapter 11: Company Profiles

  • ABBVIE INC.
    • Company Overview
    • Product Information
    • Development and Strategies
    • Financials
  • AMGEN INC.
    • Product Information
  • ASTRAZENECA PLC
    • Company Overview
    • Product Information
    • Financials
  • BOEHRINGER INGELHEIM PHARMACEUTICALS INC.
    • Company Overview
    • Financials
    • Development and Strategies
  • BRISTOL-MYERS SQUIBB CO.
    • Company Overview
    • Product Information
    • Financials
  • CELGENE CORP.
    • Company Overview
    • Product Information
    • Financials
  • GILEAD SCIENCES INC.
    • Company Overview
    • Financials
  • GLAXOSMITHKLINE PLC
    • Company Overview
    • Development and Strategies
    • Financials
  • F. HOFFMANN-LA ROCHE LTD.
    • Company Overview
    • Product Information
    • Financials
  • JANSSEN GLOBAL SERVICES LLC
    • Company Overview
    • Financials
  • MERCK & CO., INC.
    • Company Overview
    • Product Information
    • Financials
  • NOVARTIS AG
    • Company Overview
    • Product Information
    • Financials
  • PFIZER INC.
    • Company Overview
    • Product Information
    • Financials
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.
    • Company Overview
    • Product Information
    • Development and Strategies
    • Financials

Chapter 12: Appendix: Acronyms and Glossary

  • Acronyms
  • Glossary of Terms
Back to Top